Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

This study has been completed.
Information provided by:
Amphastar Pharmaceuticals, Inc. Identifier:
First received: August 24, 2010
Last updated: January 23, 2012
Last verified: January 2012
The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006, in comparison with those of an active control, Proventil®-HFA MDI, and a placebo control DPI, in escalating and cumulative-doses up to 1,440 mcg, eight (8) times of the proposed clinical dose.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Albuterol Inhalation Powder
Drug: Placebo Control
Drug: Active Comparator
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients

Resource links provided by NLM:

Further study details as provided by Amphastar Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Bronchodilatory efficacy after the escalating and cumulative-doses, up to 1,440 mcg. [ Time Frame: -15 min predose, 15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, 360 min post dose 4 ]
    Area Under the Curve (AUC)0-t of percent change in Forced Expiratory Volume in 1 second (FEV1), which is defined as the area under curve of post-dose FEV1 percentage changes from the Pre-dose Baseline FEV1 (FEV10) versus time. Doses are at 0, 30, 60 and 90 min.

Secondary Outcome Measures:
  • AUC0-t of change in FEV1 [ Time Frame: -15, 15 min post 1, 2, and 3, and 15, 90, 120, 240, and 360min post dose 4 ]
    AUC of FEV1 volume post-dose changes (change in Volume) from the Pre-dose Baseline FEV1 (FEV10). Doses are at 0, 30, 60 and 90 min.

  • Time to onset [ Time Frame: 0 - 120 min ]
    Time to onset of bronchodilatory effect, determined by linear interpolation as the point where FEV1 % change first reaches ≥ 12% from FEV10.

  • Peak Response [ Time Frame: 15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, and 360 min post dose 4 ]
    The peak bronchodilator response, defined as the maximum post-dose FEV1 % change. Doses are at time 0, 30, 60, and 90 min.

  • Adverse Events [ Time Frame: Time 0, 15, 45, 75, 105, 150, 195, 130, 190, 250, 435 minutes post dose 1 ]
    The adverse drug events (ADE) that are observed with Albuterol MDI may be expected with the use of Albuterol DPI

  • Blood Analysis [ Time Frame: -15, 10, 25,40, 55, 70, 85, 95, 115, 145, 175, 210, 270, 330, 690 min post dose 1 ]
    serum glucose and potassium analysis and PK analysis

  • Vital Signs and Electrocardiogram (ECG) [ Time Frame: -15, 5, 35, 65, 100, 155, 275, 455, 815 min post dose 1 ]
    vital signs, including pulse and blood pressure and 12-lead ECG

Enrollment: 27
Study Start Date: July 2010
Study Completion Date: January 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment 1
Albuterol Inhalation Powder escalating dose up to 180 mcg/dose, cumulative dose up to 1440 mcg, dosing at 30 min. intervals
Drug: Albuterol Inhalation Powder
Albuterol dry powder inhaler, 180 mcg/inhalation, escalating dose 180 mcg, 180 mcg, 360 mcg, 720 mcg, at 30 min intervals, total cumulative dose 1440
Other Name: A006
Active Comparator: Active Control
Proventil HFA albuterol inhalation aerosol, 90 mcg/ inhalation
Drug: Active Comparator
Proventil HFA albuterol inhalation aerosol, 90 mcg/inhalation, 2, 2, 4, and 8 inhalations per dose a 30 min intervals, total accumulated dose 1440 mcg.
Other Name: albuterol inhalation aerosol HFA
Placebo Comparator: Placebo Control
Placebo control, 0 mcg albuterol/dose, contains only lactose as carrier.
Drug: Placebo Control
Placebo control contains only lactose in amounts identical to the lactose contained in A006. 1, 1, 2, and 4 inhalation at 30 min intervals.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body weight ≥ 50 kg for men and ≥ 45 kg for women, and BMI within the range of 18.5 - 30.0 kg/m2 inclusive;
  • Sitting blood pressure ≤ 135/90 mmHg;
  • Demonstrating negative alcohol/drug screen tests;
  • Demonstrating negative HIV, HBsAg and HCV-Ab screen tests;
  • With mild-to-moderate persistent asthma for at least 6 months prior to Screening, and having used inhaled β-agonist(s) for asthma control;
  • Demonstrating a Mean Screening Baseline FEV1 at 50.0 - 85.0 % of predicted normal;
  • Demonstrating a ≥ 15.0% Airway Reversibility in FEV1 within 30(±5) min after inhaling 2 actuations of Proventil® MDI;
  • Demonstrating Peak Inspiratory Flow Rate within 80-150 L/min;
  • Demonstrating proficiency in the use of DPI and MDI after training;
  • Females of child-bearing potential must be non-pregnant, non-lactating, and practicing a clinically acceptable form of birth control;
  • Having properly consented to participate in the trial.

Exclusion Criteria:

  • Smoking history of ≥ 10 pack-years, or having smoked within 6 months prior to Screening;
  • Upper respiratory tract infections within 2 wk, or lower respiratory tract infection within 4 wk;
  • Asthma exacerbations that required emergency care or hospitalized treatment, within 4 wk prior;
  • Any current or recent respiratory conditions that might significantly affect pharmacodynamic response to the study drugs, besides asthma;
  • Concurrent clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignancies, or other illnesses that could impact on the conduct, safety and evaluation of the study;
  • Known intolerance or hypersensitivity to any of the ingredients of the study drug DPI or Proventil® MDI;
  • Use of prohibited drugs or failure to observe the drug washout restrictions;
  • Having been on other clinical drug/device studies in the last 30 days;
  • Having donated blood within the last 30 days prior to Screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01189396

United States, Oregon
Amphastar Site 4
Medford, Oregon, United States, 97504
Amphastar Site 1
Portland, Oregon, United States, 97212
United States, Texas
Ampahstar Site 3
San Antonio, Texas, United States, 78229
United States, Washington
Ampahstar Site 2
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Amphastar Pharmaceuticals, Inc.
Study Director: Medical Director, M.D., Ph.D. Amphastar Pharmaceuticals, Inc.
  More Information

Responsible Party: Medical Director, Amphastar Pharmaceuticals, Inc. Identifier: NCT01189396     History of Changes
Other Study ID Numbers: API-A006-CL-C
Study First Received: August 24, 2010
Last Updated: January 23, 2012

Keywords provided by Amphastar Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Bronchial Spasm
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 27, 2017